OR WAIT 15 SECS
Medidata Solutions today announced that Progenics Pharmaceuticals, Inc. has selected the Medidata Rave® electronic data capture (EDC) and clinical data management (CDM) platform. Progenics has decided to implement Rave integrated with United BioSource Corp’s (UBC) interactive voice response system (IVRS) to manage a Phase III study evaluating methylnaltrexone, an opioid-induced constipation treatment, throughout investigative sites in Europe, Canada and the U.S.
Based in Tarrytown, NY, Progenics focuses on innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases, with principal programs directed toward supportive care, oncology and infectious diseases.
To implement the integration process, UBC also provided a unified project management system for multi-technology implementation and integration. UBC has strategically partnered with Medidata for a number of years, joining the Medidata ASPire to Win® partner program for contract research organizations in 2007 and becoming a Medidata Technology Partner for its IVRS integration with Rave in 2009.